به جمع مشترکان مگیران بپیوندید!

تنها با پرداخت 70 هزارتومان حق اشتراک سالانه به متن مقالات دسترسی داشته باشید و 100 مقاله را بدون هزینه دیگری دریافت کنید.

برای پرداخت حق اشتراک اگر عضو هستید وارد شوید در غیر این صورت حساب کاربری جدید ایجاد کنید

عضویت
فهرست مطالب نویسنده:

amirreza dowlati beirami

  • محمدحسین متولی، امیررضا دولتی بیرامی، علیرضا سلیمی، نازیلا یوسفی*
    زمینه و هدف

    حمایت از تولید داخل، با فرض تاثیر بر افزایش دسترسی، از 2 بعد فراهمی بهتر داروها در بازار و استطاعت پذیری از طریق کاهش قیمت ها به عنوان یکی از سیاست های اصلی دارویی تایید گردیده است. لذا، انتظار می رود صنعت تولید داخل، محصولات دارویی تولید نماید که علاوه بر کمک به افزایش دسترسی و فراهمی داروها و تامین پایدار آن ها، قیمت هایی رقابتی نسبت به رقبای وارداتی داشته باشند و هزینه های دارویی بیماران و نظام سلامت را کاهش دهند. در مطالعه حاضر قیمت داروهای تولید داخل با قیمت داروهای ژنریک مشابه در کشور هند مورد مقایسه قرار گرفته است.

    روش پژوهش

    در این مطالعه، ابتدا کشور هند با دلایلی از جمله قیمت پایین و کیفیت مناسب، و امکان پذیری تجارت در شرایط تحریم برای مقایسه انتخاب گردید. سپس از آمارنامه دارویی ایران داروهایی که صرفا تولید داخل و مصرف قابل توجهی از نظر فروش عددی و ریالی دارند، وارد مطالعه شدند. قیمت دارو ها از سایت های معتبر مورد تایید سازمان های نظارتی در ایران و هند استخراج شدند. در نهایت قیمت 110 قلم دارو مورد مقایسه قرار گرفتند تا میزان موفقیت صنعت تولید داخل در ارایه قیمت مناسب در عدم حضور رقبای خارجی مشخص شود.

    یافته ها

    با توجه به نتایج به دست آمده در 57 درصد داروهای مورد مطالعه، میانه ی قیمت مصرف کننده ی این داروها در هند پایین تر از قیمت مصرف کننده ی ایرانی بود؛ درصورتیکه این مقایسه با کمینه ی قیمت داروهای هندی انجام شود، این درصد به 88 افزایش خواهد یافت.

    نتیجه گیری

    با توجه به بررسی فوق به نظر می رسد کاهش قیمت ها و هزینه های دارویی در تمام موارد تولید داخل رخ نمی دهد و این امر به تنهایی نمی تواند توجیه مناسبی برای حمایت از تولید داخلی داروها به صورت مطلق باشد؛ اما باید توجه داشت که کاهش هزینه ها تنها دلیل حمایت از تولید داخل این محصولات نبوده و سیاستگذار ممکن است با توجه به عوامل دیگری در راستای سیاست های حمایتی اقدام نماید؛ لیکن در هر مورد این دلایل بایستی برای نظام سلامت معین باشد.

    کلید واژگان: محصول نهایی دارویی, قیمت, تولید داخلی, داروهای ژنریک
    Mohammad Hosein Motevalli, Amirreza Dowlati Beirami, Alireza Salimi, Nazila Yousefi*
    Background

    Supporting domestic production, by assuming its effect on the increase of accessibility, has been acknowledged as one of the main pharmaceutical policies from two dimensions of better provision of the drugs in the market and the increase of affordability by reducing prices. Therefore, it is expected from the domestic industries to produce pharmaceutical products that, in addition to increasing access and a sustainable supply of drugs, have competitive prices compared to the rival imported products, and reduce the medical costs imposed on patients and the health system. In this study the price of domestically produced drugs were compared with the price of the similar generic ones in India.

    Methods

    In this study, first, India was selected for comparison due to reasons such as low price, good quality, and the possibility of commerce despite sanctions. Then, from the Iranian pharmaceutical statistics, drugs which were only produced in Iran and were highly consumed with respect to the number of sales were included in the study. Prices of Iranian and Indian medicines were extracted from related valid websites. Finally, the price of 110 drugs were compared to determine the success rate of the domestic production industry in offering a reasonable price in the absence of foreign competitors.

    Results

     According to the findings from 57 % of the drugs under study, the median consumer price of these drugs in India was lower than the Iranian consumer price. If this comparison was made with the minimum price of the Indian medicine, this percentage would reach 88.

    Conclusion

    According to the findings mentioned above, it can be concluded that reducing the drugs prices and costs does not occur in all cases of domestic production, and this alone cannot be a good justification for a complete support of the domestic production of drugs; however, it should be noted that reducing costs is not the only reason to support domestic production of these products, and policy makers may act with regard to other factors in line with supportive policies; thus,  the reasons regarding each case should be clearly defined for the health system.

    Keywords: Pharmaceutical finished product, price, Domestic production, Drugs, Generic
  • Dara Hatamabadi, Bahar Mostafiz, Amirreza Dowlati Beirami, Kamran Banan, Niloufar Sharafi Tafreshi Moghaddam, Hanif Afsharara, Rustem Kecili, Fatemeh Ghorbani Bidkorbeh *

    The process of matrix clean-up and extraction of analytes has a significant influence on the detection and determination of the analyte, especially in trace amounts. Molecularly imprinted polymers (MIPs) are solid particles that can absorb specific molecules regarding the template molecule used in the synthesis process of each type of MIP. As a result, they can be used in more effective and more specific solid-phase extraction processes. On the others hand, mycotoxins are second metabolites of molds and fungus which are potentially cytotoxic and/or genotoxic even in trace amounts, and due to extensive consumption of cereals and the great concern of public health, several methods were developed and currently are in the process of development to detect and determine the presence and the amounts of mycotoxins in cereals. This review is aimed to investigate the application and efficacy of MIPs in detecting and determination of mycotoxins in cereals.

    Keywords: Cereal, Molecularly imprinted polymer, Detection, Determination, Mycotoxins
  • Arash Dooghaie Moghadam, Pegah Eslami, Amirreza Dowlati Beirami, Shahrokh Iravani, Ermia Farokhi, Alireza Mansour Ghanaei, MahmoodReza Hashemi, Morteza Aghajanpoor Pasha, Azim Mehrvar, Mohssen Nassiri Toosi

    Currently, liver transplantation (LT) is considered as the only option for the treatment of patients with various causes of liver failure, including patients with chronic hepatitis B virus (HBV) infections. Overall, patients with HBV who undergo LT are at increased risk of hepatitis B infection recurrence. Although the current knowledge regarding the pathophysiology of this infection has been dramatically increased over the past few decades, it is still considered a complex disease process with varying degrees of clinical characteristics and changing patterns over time. There are various treatment strategies for preventing HBV recurrence in the LT setting. Generally, these regimens include oral nucleoside/ nucleotide analogues (NAs), hepatitis B immune globulin (HBIG), and vaccines or the combination of these drugs. The treatment strategy of choice should be based on costeffectiveness, along with other patients underlying conditions. In this case, studies indicate that potent NAs are more cost-effective than HBIG in most case scenarios. In this article, we aimed to review the general medications used in the prophylaxis of the recurrence of HBV infection after LT

    Keywords: Liver transplantation, Hepatitis B, Treatment
  • Roya Atabakhshian, Siamak Salami, Reza Mirfakhraie, Somayeh Mahmoodi Khatonabadi, Majid Sirati-Sabet, Bahram Gholamali Yaghmaei, Shiva Ghafghazi, Amirreza Dowlati Beirami, Mitra Sadat Rezaei, Seyed Ali Ziai*
    Background and objectives

    Umbelliprenin, a prenylated coumarin from different species of Ferula, has demonstrated anti-cancer effects in various types of cancer cells, but the potential molecular mechanisms for the anti-angiogenic activity of umbelliprenin in breast cancer cells have not yet been studied.  In this study, we investigated the possible molecular pathways involved in the anti-angiogenic effect of umbelliprenin in EGF and CoCl2 stimulated SKBR-3 breast cancer cells.

    Methods

    Effects of umbelliprenin on the changes in EGFR signaling genes (EGFR, PI3K, AKT, mTOR, S6K, 4EBP1, ERK1/2, HIF-1α, HIF-1β, VEGF, VEGFR) and proteins (VEGF/HIF-1α) expression were assayed in SKBR-3 via Quantitative PCR and Western blotting assays.

    Results

    Umbelliprenin dramatically decreased the living cells in a concentration related manner (IC50=103.9 µM) and non- toxic doses of umbelliprenin IC5 and IC10 (10 and 20 µM, respectively) were used for evaluating in vitro anti-angiogenic effects. Umbelliprenin significantly reduced pro-angiogenic AKT, ERK1, ERK2, mTOR, S6K, HIF-1α, HIF-1b, VEGF and VEGFR mRNAs in EGF-treated, and  AKT, ERK2, S6K, HIF-1α, HIF-1b, VEGF and VEGFR mRNAs in CoCl2-treated cells. Umbelliprenin significantly increased anti-angiogenic 4EBP1 mRNA in EGF / CoCl2-treated cells. It significantly decreased the levels of HIF-1α and VEGF proteins, in CoCl2-treated cells.

    Conclusion

    Our findings showed that umbelliprenin exhibits anti-angiogenic effects by decreasing the expression of AKT/mTOR/MAPK angiogenesis pathways in EGF or CoCl2 treated SKBR-3 breast cancer cells.

    Keywords: Angiogenesis, breast cancer, COCl2, EGF, umbelliprenin
  • Amirreza Dowlati Beirami, Dara Hatamabadi, Sayna Iranpanah, Mitrasadat Rezaei, Seyed Ali Ziai*
    Background

    The COVID-19 pandemic is a global health emergency caused by SARS-CoV-2. Unfortunately, no effective drugs have been found to date. There is also a major need for new therapies to treat this disease. The main protease is an attractive drug target among coronaviruses due to its important role in the processing of viral RNA-translated polyproteins. Objective of This study was conducted to screen data-bases of herbal compounds for potential main protease inhibitors.

    Material and Methods

    Natural products from 3 database banks were first tested and filtered by ADME / toxicity, then their molecular energy was minimized, and finally, they were docked into the SARS-CoV-2 main protease and compared with indinavir.

    Results

    The binding energies of 6570 molecules from different herbal compounds comprising databases were tested and five of the molecules with the highest binding energies for SARS-CoV-2 main protease docking were selected and key interactions were studied.

    Conclusion

    In conclusion, five herbal compounds including Sodwanone B, Cyclo-mulberrin, and a glycosylated derivative of kaempferol had lower docking energy com-pared to indinavir and were suggested for further research.

    Keywords: COVID-19, SARS-CoV-2, Protease, Nat-ural products, Medicinal plants
  • Shahrokh Iravani*, Arash Dooghaie Moghadam, Niloofar Razavi Khorasani, Bobak Moazzami, Amirreza Dowlati Beirami, Alireza Mansour, Ghanaei, Keivan Majidzadeh A, Azim Mehrvar, Alireza Khoshdel, Mohssen Nasiri Toosi, Amir Sadeghi

    Primary sclerosing cholangitis is a chronic cholestatic liver disease defined by strictures of the biliary tree which could ultimately lead to liver cirrhosis and cholangiocarcinoma. Although the exact underlying etiology of this disorder is not fully understood, the pathology is believed to be caused by immune mediated mechanisms. Growing body of evidence suggests several treatment modalities mainly focusing on the inflammation aspect of this disorder. However, there is still no consensus regarding the best treatment option for these patients. Thus, the present study aimed to review the current treatment options for patients with primary sclerosing cholangitis.

    Keywords: Inflammatory bowel disease, Primary sclerosing cholangitis (PSC), Management, Vancomycin, Cholestasis, Cholangitis
بدانید!
  • در این صفحه نام مورد نظر در اسامی نویسندگان مقالات جستجو می‌شود. ممکن است نتایج شامل مطالب نویسندگان هم نام و حتی در رشته‌های مختلف باشد.
  • همه مقالات ترجمه فارسی یا انگلیسی ندارند پس ممکن است مقالاتی باشند که نام نویسنده مورد نظر شما به صورت معادل فارسی یا انگلیسی آن درج شده باشد. در صفحه جستجوی پیشرفته می‌توانید همزمان نام فارسی و انگلیسی نویسنده را درج نمایید.
  • در صورتی که می‌خواهید جستجو را با شرایط متفاوت تکرار کنید به صفحه جستجوی پیشرفته مطالب نشریات مراجعه کنید.
درخواست پشتیبانی - گزارش اشکال